Search research articles
Contact Us
Filters
Showing results (31-40 of 57) with videos related to
Page
of 6
Sort By:
European Heart Journal. Cardiovascular Pharmacotherapy
|
April 22, 2024
Edoxaban for 12 vs. 3 months in cancer-associated isolated distal deep vein thrombosis according to different doses: insights from the ONCO DVT study
Ryuki Chatani, Yugo Yamashita, Takeshi Morimoto, et al.
Blood Vessels, Thrombosis & Hemostasis
|
August 6, 2025
D-dimer after 3 months of anticoagulation therapy and outcomes in cancer-associated isolated distal deep vein thrombosis
Tatsuya Nishikawa, Yugo Yamashita, Masashi Fujita, et al.
Thrombosis Research
|
September 10, 2025
The influence of metastasis on clinical outcomes in patients with cancer-associated isolated distal deep vein thrombosis: A pre-specified subgroup analysis from the ONCO DVT study
Michihisa Umetsu, Yugo Yamashita, Takeshi Morimoto, et al.
Journal of Thrombosis and Thrombolysis
|
April 8, 2019
Clinical experience of idarucizumab use in cases of cardiac tamponade under uninterrupted anticoagulation of dabigatran during catheter ablation of atrial fibrillation
Kaoru Okishige, Yasuteru Yamauchi, Yuichi Hanaki, et al.
Circulation
|
November 18, 2024
Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)
Yugo Yamashita, Takeshi Morimoto, Nao Muraoka, et al.
Journal of the American Heart Association
|
October 22, 2024
Incidence of Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Embolism in the Era of Direct Oral Anticoagulants: From the COMMAND VTE Registry-2
Nobutaka Ikeda, Yugo Yamashita, Takeshi Morimoto, et al.
Circulation
|
August 28, 2023
Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis (ONCO DVT Study): An Open-Label, Multicenter, Randomized Clinical Trial
Yugo Yamashita, Takeshi Morimoto, Nao Muraoka, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society
|
March 10, 2024
Home Treatment for Active Cancer Patients With Low-Risk Pulmonary Embolism - A Predetermined Companion Report From the ONCO PE Trial
Ryuki Chatani, Yugo Yamashita, Takeshi Morimoto, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society
|
December 22, 2024
Newly Diagnosed Cancer After Diagnosis of Venous Thromboembolism - Insights From the COMMAND VTE Registry-2
Yugo Yamashita, Takeshi Morimoto, Ryuki Chatani, et al.
Journal of the American Heart Association
|
September 30, 2024
Selection of Home Treatment and Identification of Low-Risk Patients With Pulmonary Embolism Based on Simplified Pulmonary Embolism Severity Index Score in the Era of Direct Oral Anticoagulants
Ryusuke Nishikawa, Yugo Yamashita, Takeshi Morimoto, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 57) with videos related to
Sort By:
Page
of 6
European Heart Journal. Cardiovascular Pharmacotherapy
|
April 22, 2024
Edoxaban for 12 vs. 3 months in cancer-associated isolated distal deep vein thrombosis according to different doses: insights from the ONCO DVT study
Ryuki Chatani, Yugo Yamashita, Takeshi Morimoto, et al.
Blood Vessels, Thrombosis & Hemostasis
|
August 6, 2025
D-dimer after 3 months of anticoagulation therapy and outcomes in cancer-associated isolated distal deep vein thrombosis
Tatsuya Nishikawa, Yugo Yamashita, Masashi Fujita, et al.
Thrombosis Research
|
September 10, 2025
The influence of metastasis on clinical outcomes in patients with cancer-associated isolated distal deep vein thrombosis: A pre-specified subgroup analysis from the ONCO DVT study
Michihisa Umetsu, Yugo Yamashita, Takeshi Morimoto, et al.
Journal of Thrombosis and Thrombolysis
|
April 8, 2019
Clinical experience of idarucizumab use in cases of cardiac tamponade under uninterrupted anticoagulation of dabigatran during catheter ablation of atrial fibrillation
Kaoru Okishige, Yasuteru Yamauchi, Yuichi Hanaki, et al.
Circulation
|
November 18, 2024
Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)
Yugo Yamashita, Takeshi Morimoto, Nao Muraoka, et al.
Journal of the American Heart Association
|
October 22, 2024
Incidence of Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Embolism in the Era of Direct Oral Anticoagulants: From the COMMAND VTE Registry-2
Nobutaka Ikeda, Yugo Yamashita, Takeshi Morimoto, et al.
Circulation
|
August 28, 2023
Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis (ONCO DVT Study): An Open-Label, Multicenter, Randomized Clinical Trial
Yugo Yamashita, Takeshi Morimoto, Nao Muraoka, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society
|
March 10, 2024
Home Treatment for Active Cancer Patients With Low-Risk Pulmonary Embolism - A Predetermined Companion Report From the ONCO PE Trial
Ryuki Chatani, Yugo Yamashita, Takeshi Morimoto, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society
|
December 22, 2024
Newly Diagnosed Cancer After Diagnosis of Venous Thromboembolism - Insights From the COMMAND VTE Registry-2
Yugo Yamashita, Takeshi Morimoto, Ryuki Chatani, et al.
Journal of the American Heart Association
|
September 30, 2024
Selection of Home Treatment and Identification of Low-Risk Patients With Pulmonary Embolism Based on Simplified Pulmonary Embolism Severity Index Score in the Era of Direct Oral Anticoagulants
Ryusuke Nishikawa, Yugo Yamashita, Takeshi Morimoto, et al.
Page
of 6